4553

TOWA PHARMACEUTICAL CO.,LTD.

東和薬品株式会社
Pharmaceutical
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In addition, the company is involved in research and development and production of active pharmaceutical ingredients, intermediates, support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. The company was founded in 1951 and is headquartered in Osaka, Japan.
← Companies
Price
¥3,950
Market Cap
¥194.4B
Ent. Value
¥366.8B
Net Debt
−¥172.3B
Shares Out.
49.2M
P / E
10.2×
EV / EBIT
1.3×
P / Book
1.13×
P / NCAV
N/M
Div. Yield
1.77%
Financials
Metric FY 2025
TDnet 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥280.0B ¥259.6B ¥227.9B ¥208.9B ¥165.6B
Cost of Sales — ¥164.9B ¥146.6B ¥136.1B ¥95.4B
Gross Profit — ¥94.7B ¥81.4B ¥72.7B ¥70.2B
SG&A — ¥71.5B ¥63.7B ¥67.2B ¥51.0B
Operating Income ¥280.0B ¥23.2B ¥17.6B ¥5.5B ¥19.2B
Non-Operating Income — ¥4.9B ¥8.1B ¥2.9B ¥4.5B
Dividend Income — ¥11M ¥9M ¥8M ¥6M
Interest Income — ¥221M ¥97M ¥17M ¥8M
Non-Operating Expenses — ¥2.0B ¥1.3B ¥3.3B ¥1.0B
Interest Expense — ¥1.6B ¥947M ¥635M ¥230M
Ordinary Income ¥280.0B ¥26.2B ¥24.5B ¥5.1B ¥22.7B
Pre-tax Income — ¥26.3B ¥24.5B ¥4.6B ¥22.2B
Income Taxes — ¥7.3B ¥8.3B ¥2.4B ¥6.3B
Current Tax — ¥8.1B ¥8.8B ¥3.0B ¥6.2B
Deferred Tax — ¥-715M ¥-532M ¥-633M ¥176M
Net Income (owners) ¥1M ¥19.0B ¥16.2B ¥2.2B ¥15.9B
Comprehensive Income — ¥18.6B ¥21.9B ¥7.8B ¥18.0B
EBITDA — ¥43.3B ¥35.5B ¥24.9B ¥30.2B
Goodwill Amort. (J-GAAP) — ¥4.4B ¥4.2B ¥5.1B ¥801M
EPS — ¥385.71 ¥328.59 ¥44.72 ¥323.36
Shares Outstanding — 49.2M 49.2M 49.2M 49.2M
Shares Issued (total) — 51.5M 51.5M 51.5M 51.5M
Treasury Shares — 2.3M 2.3M 2.3M 2.3M